

Table S1: Clinical baseline characteristics

patient	sex	age [y]	EF	LVEDD	genotype
III.2	m	41	20	82	<i>TTN</i> p.Glu8271Gln+p.Lys23669Ter
III.3	f	60	59	44	<i>RBM20</i> p.Gly603Arg+p.Glu792GlyfsTer9
IV.3	m	34	10	71	<i>TTN</i> p.Glu8271Gln+p.Lys23669Ter <i>RBM20</i> p.Gly603Arg+p.Glu792GlyfsTer9
IV.8	m	23	15-20	68	<i>TTN</i> p.Glu8271Gln+p.Lys23669Ter
IV.9	m	23	35	n.a.	( <i>TTN</i> p.Glu8271Gln+p.Lys23669Ter)

Data were acquired either at the time of myocardial tissue sampling (left ventricular assist device implantation for III.2 and IV.8 or total artificial heart implantation for IV.3) or at the time of the last available cardiologic examination (III.3 and IV.9). f=female, m=male, EF=ejection fraction in %, LVEDD=left ventricular end diastolic diameter in mm, n.a.=not available, wt=wildtype, y=years. The genotype of IV.9 is given in brackets as the patient is a monozygotic twin of IV.8 but was not genotyped.